Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Dow, Geoffrey S ^a   Milner, Erin ^a   Bathurst, Ian ^b   Bhonsle, Jayendra ^a   Caridha, Diana ^a   Gardner, Sean ^a   Gerena, Lucia ^a   Kozar, Michael ^a   Lanteri, Charlotte ^a   Mannila, Anne ^c   McCalmont, William ^a   Moon, Jay ^a   Read, Kevin D ^d   Norval, Suzanne ^d   Roncal, Norma ^a   Shackleford, David M ^c   Sousa, Jason ^a   Steuten, Jessica ^c   White, Karen L ^c   Zeng, Qiang ^a   Charman, Susan A ^c   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b International Center Cointrin   (Switzerland)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMINE DERIVATIVE; MEFLOQUINE; METHANOL DERIVATIVE; QUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; QUINOLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; FEASIBILITY STUDY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; ANIMAL; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; PLASMA; TIME;

ANIMALS; ANTIMALARIALS; CENTRAL NERVOUS SYSTEM; INJECTIONS, INTRAVENOUS; MALE; MEFLOQUINE; MICE; PLASMA; QUINOLINES; TIME FACTORS;

EID: 79957880657     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-150     Document Type: Article

References (20)

1. Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. GS Dow AJ Magill C Ohrt, Ther Clin Risk Manag 2008 4 803 819 19209263
2. The IPTi Consortium: research for policy and action. D Schellenberg B Ci (Pubitemid 43964897)
3. Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis. GD Shanks AJ Magill DO Freedman JS Keystone DJ Bradley R Steffen, Am J Trop Med Hyg 2007 77 1 2 18165468 (Pubitemid 351844343)
4. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. P Rendi-Wagner H Noedl WH Wernsdorfer G Weidermann A Mikolasek H Kollaristch, Acta Trop 2002 81 167 173 10.1016/S0001-706X(01)00210-8 11801224 (Pubitemid 34093807)
5. Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin. A Caridha D Yourick M Cabezas L Wolf TH Hudson GS Dow, Antimicrob Agent Chemother 2008 52 684 693 10.1128/AAC.00874-07 (Pubitemid 351170845)
6. Mefloquine induces dose-related neurological effects in a rat model. G Dow R Bauman D Caridha M Cabezas F Du R Gomez-Lobo M Park K Smith K Cannard, Antimicrob Agent Chemother 2006 50 1045 1053 10.1128/AAC.50.3.1045-1053.2006 (Pubitemid 43327810)
7. Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. E Milner W McCalmont J Bhonsle C Caridha D Carroll S Gardner L Gerena M Gettayacamin C Lanteri T Luong V Melendez J Moon N Roncal J Sousa A Tangtaeng P Wipf GS Dow, Bioorg Med Chem Lett 2010 20 1347 1351 20097070
8. Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols. E Milner W McCalmont J Bhonsle D Caridha J Cobar S Gardner L Gerena D Goodine C Lanteri V Melendez N Roncal J Sousa P Wipf G Dow, Malar J 2010 9 51 10.1186/1475-2875-9-51 20149249
9. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. PH Rendi-Wagner H Noedl WH Wernsdorfer G Weidermann A Mikolasek H Kollaritsch, Acta Trop 2002 81 167 173 10.1016/S0001-706X(01)00210-8 11801224 (Pubitemid 34093807)
10. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. D Overbosch H Schilthuis U Bienzle RH Behrens KC Kain PD Clarke S Toovey J Knobloch HD Nothdurft D Shaw NS Roskell JD Chulay, Clin Infect Dis 2001 33 1015 1021 10.1086/322694 11528574 (Pubitemid 32907104)
11. Drug-like properties and the causes of poor solubility and poor permeability. CA Lipinski, J Pharmacol Toxicol Methods 2000 44 235 249 10.1016/S1056-8719(00)00107-6 11274893 (Pubitemid 32239479)
12. Drug-like properties: concepts, structure design and methods. EH Kerns L Di, Burlington, MA, Elsevier Inc 2008 35 100
13. Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction. SG Summerfield K Read DJ Begley T Obradovic IJ Hidalgo S Coggon AV Lewis RA Porter P Jeffrey, JPET 2007 322 205 213 10.1124/jpet.107.121525 (Pubitemid 46956363)
14. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. JC Kalvass TS Maurer, Biopharmaceutics Drug Disp 2002 23 327 338 10.1002/bdd.325 (Pubitemid 36124162)
15. Thermodynamics of partitioning of the antimalarial drug mefloquine in phospholipid bilayers and bulk solvents. ML Go TL Ngiam, Chem Pharm Bull 1997 45 2055 2060 9433777
16. A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with dipalmitoylphosphatidylcholine bilayers. R Zidovetzki IW Sherman A Attiya H De Boeck, Mol Biochem Parasitol 1989 35 199 207 10.1016/0166-6851(89)90206-5 2787476
17. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. RE Desjardins CJ Canfield JD Haynes JD Chulay, Antimicrob Agents Chemother 1979 16 710 718 394674 (Pubitemid 10082023)
18. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. WK Milhous NF Weatherly JH Bowdre RE Desjardins, Antimicrob Agents Chemother 1985 27 525 530 3890727 (Pubitemid 15097653)
19. Kucer's Use of Antibiotics. GS Dow AJ Magill, ASM Press, Washington DC, Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL and Pfaller MA, Sixth 2008 2024 2035 "Mefloquine"
20. How to improve R&D productivity: the pharmaceutical industry's grand challenge. MS Paul DS Mytelka CT Dunwiddie CC Persinger BH Munos SR Lindborg AL Schacht, Nat Rev Drug Discovery 2010 9 203 214